Thus, combining molecular subtyping and IGHG2 ratio, we maximized the RNA-seq usage to stratify ESCC patients, which could be helpful in identifying clinical interventions to improve clinical outcomes. This evidence concerns the gene IGHG2 and esophageal squamous cell carcinoma.